You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Mendeley readers
| Chapter title |
Afatinib
|
|---|---|
| Chapter number | 14 |
| Book title |
Small Molecules in Oncology
|
| Published in |
Recent results in cancer research Fortschritte der Krebsforschung Progrès dans les recherches sur le cancer, January 2018
|
| DOI | 10.1007/978-3-319-91442-8_14 |
| Pubmed ID | |
| Book ISBNs |
978-3-31-991441-1, 978-3-31-991442-8
|
| Authors |
Helga Wecker, Cornelius F. Waller, Wecker, Helga, Waller, Cornelius F. |
| Abstract |
Afatinib (BIBW 2992, US: GilotrifTM, other countries: Giotrif©) is an irreversible blocker of the ErbB family, acting at the tyrosine kinases of these proteins. In 2013, it was approved by the FDA and the EMA for the treatment of adults with advanced, EGFR mutation-positive non-small-cell lung cancer. Further investigations for the treatment of many other tumors with afatinib, e.g., HNSCC and breast cancer, are ongoing. |
Mendeley readers
The data shown below were compiled from readership statistics for 117 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 117 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 21 | 18% |
| Researcher | 15 | 13% |
| Student > Master | 11 | 9% |
| Student > Ph. D. Student | 8 | 7% |
| Other | 5 | 4% |
| Other | 14 | 12% |
| Unknown | 43 | 37% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 23 | 20% |
| Biochemistry, Genetics and Molecular Biology | 15 | 13% |
| Pharmacology, Toxicology and Pharmaceutical Science | 11 | 9% |
| Chemistry | 7 | 6% |
| Agricultural and Biological Sciences | 3 | 3% |
| Other | 10 | 9% |
| Unknown | 48 | 41% |